|
| Press Releases |
|
 |
|
| Tuesday, May 28, 2024 |
|
|
CR Pharmaceutical Armed with Leading Advantages Releases Growth Potential and Achieves High-quality Sustainable Development |
| China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320.HK), recorded total revenue of RMB244,703.9 million last year, a 12.2% climb year-on-year, and net profit of RMB 7,775.0 million, a 16.8% increase year-on-year. more info >> |
|
| Monday, November 14, 2022 |
|
|
CR Pharmaceutical Becomes Constituent of MSCI China Index Once Again |
| China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320) has announced that the Group will once again be included as a constituent stock of the MSCI China Index, which will become effective after the market close on 30 November 2022. more info >> |
|
| Monday, January 20, 2020 |
|
|
安捷證券第二輪藥品集採結果：降價主旋律不變，首推創新型龍頭 |
| 2020年01月17日，第二輪國家集採正式開標，結果如下：122家企業參與採購，33個(按通用名計)藥品的194個品規激烈厮殺，價格降幅超出市場預期。 more info >> |
|
| Tuesday, July 2, 2019 |
|
|
华润医药再度蝉联资本杰出中国企业成就奖 |
华润医药集团有限公司（「华润医药」或「集团」；股份编号：3320）欣然宣布，集团于《资本杂志》主办的第十四届「资本杰出中国企业成就奖」中再度获选为「资本杰出中国医药集团」，彰显集团在过去一年于业务上的杰出表现及其稳固的发展潜力。
more info >> |
|
|
華潤醫藥再度蟬聯資本傑出中國企業成就獎 |
華潤醫藥集團有限公司（「華潤醫藥」或「集團」；股份編號：3320）欣然宣佈，集團於《資本雜誌》主辦的第十四屆「資本傑出中國企業成就獎」中再度獲選為「資本傑出中國醫藥集團」，彰顯集團在過去一年於業務上的傑出表現及其穩固的發展潛力。
more info >> |
|
| Friday, August 25, 2017 |
|
|
华润医药中期业绩增长理想 实现收益约港币827亿元 |
| 华润医药集团有限公司（「华润医药」）或「集团」；股份编号：3320）公布截至2017年6月30日止年度（「期内」）的中期业绩。 more info >> |
|
|
華潤醫藥中期業績增長理想 實現收益約港幣827億元 |
| 華潤醫藥集團有限公司（「華潤醫藥」）或「集團」；股份編號：3320）公佈截至2017年6月30日止年度（「期內」）的中期業績。 more info >> |
|
|
China Resources Pharmaceutical Delivers Solid Interim Results; Half-year Revenue Reaches HK$82.7 Billion |
| China Resources Pharmaceutical Group Limited ("CR Pharmaceutical" or the "Group") (stock code: 3320), announced its interim results for the six months ended 30 June 2017 ("Reporting Period"). more info >> |
|
| Monday, March 20, 2017 |
|
|
华润医药全年业绩稳健增长 实现收益约港币1,567亿元 |
华润医药集团有限公司（「华润医药」）或「集团」；股份编号：3320）公布截至2016年12月31日止年度（「年内」）的全年业绩。
more info >> |
|
|
華潤醫藥全年業績穩健增長 實現收益約港幣1,567億元 |
華潤醫藥集團有限公司（「華潤醫藥」）或「集團」；股份編號：3320）公佈截至2016年12月31日止年度（「年內」）的全年業績。
more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
「依拉環素臨床應用綜合評價項目」終期報告發佈
Nov 26, 2024 11:11 HKT/SGT
|
|
|
'依拉环素临床应用综合评价项目'终期报告发布
Nov 26, 2024 11:04 HKT/SGT
|
|
|
Propel Global Reports Encouraging 24.2% Growth in Revenue to RM34.3 Million in Q1 FY2025
Nov 26, 2024 11:00 HKT/SGT
|
|
|
富士通、社会課題解決に向けて自治体施策の効果を最大化する「Policy Twin」技術を開発
Nov 26, 2024 11:00: JST
|
|
|
Fujitsu develops Policy Twin, a new digital twin technology to maximize effectiveness of local government policies for solving societal issues
Nov 26, 2024 10:51 JST
|
|
|
GoDaddy's Airo solution is helping Asian entrepreneurs save time
Nov 26, 2024 08:00 HKT/SGT
|
|
|
Hola Prime Sets New Industry Standard as the World's Top Transparent Prop Trading Firm
Nov 25, 2024 23:00: JST
|
|
|
Hola Prime Sets New Industry Standard as the World's Top Transparent Prop Trading Firm
Nov 25, 2024 22:00 HKT/SGT
|
|
|
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Nov 25, 2024 22:00 HKT/SGT
|
|
|
福瑞泰克赴港IPO 上汽北汽东风吉利等多家头部车企为股东
Nov 25, 2024 21:15 HKT/SGT
|
|
|
福瑞泰克赴港IPO 上汽北汽東風吉利等多家頭部車企為股東
Nov 25, 2024 21:10 HKT/SGT
|
|
|
TOPVISION Launches Prospectus for the Transfer of Listing from the LEAP Market to ACE Market
Nov 25, 2024 21:00 HKT/SGT
|
|
|
KOSPET Launches M3 Ultra and T3 Ultra Rugged Smartwatches in Malaysia, Redefining Durability and Innovation
Nov 25, 2024 20:45 HKT/SGT
|
|
|
S&P Acknowledges Fosun's Return to the USD Bond Market
Nov 25, 2024 20:30 HKT/SGT
|
|
|
Military Metals Issues Invitation to Tender for Resource Estimation at Its Trojarova Antimony-Gold Property in Slovakia
Nov 25, 2024 20:09 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
